Endo Counts On Vasostrict Revenues Despite Competition
As Company Focuses On ‘Optimizing’ Its Generics Business
Endo still sees significant potential in Vasostrict despite the onset of competition. Meanwhile, the firm says it is focusing on “optimizing” its generics business.
You may also be interested in...
Endo’s Par has announced the first launch under a longstanding US collaboration with 505(b)(2) specialist Nevakar, in the form of pre-mixed ephedrine sulfate injection in a ready-to-use 50mg/10ml single-use vial.
With Eagle set to launch its long-awaited vasopressin ANDA product on 17 January, the US firm’s management told investors it was unsure what its launch meant for the 505(b)(2) rival product in the hands of American Regent.
Endo’s Par Pharmaceutical has begun shipping the first generic version of Merz’s Cuvposa (glycopyrrolate) 1mg/5ml oral solution in the US following FDA approval.